Business
NeurAxis Reports Strong First Quarter 2025 Financial Results Driven by a 39% Growth in Revenues
Conference call will be held today, Monday, May 12 at 9:00 am ETCARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025. 1Q25 Financial highlights Revenues increased 39% year over year to $896 thousand in 1Q25 compared
About this update from Neuraxis, Inc.
[{"type":"image","alt":"NeurAxis, Inc.","displaySize":"","headline":null,"caption":"NeurAxis, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":89,"url":"https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/26D4nWOeQUW1.Tx0Xl.qeg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTEyNTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/53c594c0241aa2985511c98a9154c355","width":300,"height":89}},"lazy":false},{"type":"text","content":"Conference call will be held today, Monday, May 12 at 9:00 am ET","length":64,"tagName":"p"},{"type":"text","content":"CARMEL, Ind., May 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the first quarter 2025 for the period ended March 31, 2025.","length":338,"tagName":"p"},{"type":"text","content":"1Q25 Financial highlights","length":25,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Revenues increased 39% year over year to $896 thousand in 1Q25 compared to $647 thousand in 1Q24.","length":97,"tagName":"p"}]},{"val":[{"type":"text","content":"Revenues increased 18% quarter over quarter to $896 thousand in 1Q25 compared to $761 thousand in 4Q24.","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating loss (excluding a one-time legal settlement) improved by 9% compared to the first quarter of 2024.","length":108,"tagName":"p"}]},{"val":[{"type":"text","content":"Cash balance was $2.0 million as of March 31, 2025.","length":51,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":359,"olType":false},{"type":"text","content":"Recent Operational Highlights","length":29,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Expanded total covered lives to approximately 51 million compared to 4 million as of December 31 2023.","length":102,"tagName":"p"}]},{"val":[{"type":"text","content":"Received a new Current Procedural Terminology (CPT) Category I code for Percutaneous Electrical Nerve Field Stimulation (PENFS) procedures effective January 1, 2026.","length":165,"tagName":"p"}]},{"val":[{"type":"text","content":"Received new FDA clearance for the...